Status:
UNKNOWN
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Hepatitis C Virus Infection
Hepatitis C Virus Infection, Response to Therapy of
Eligibility:
All Genders
20+ years
Brief Summary
Chronic hepatitis C virus (HCV) infection remains a health burden in people living with human immunodeficiency virus (HIV). Interferon (IFN)-based therapy is the treatment of choice for HCV infection ...
Detailed Description
Chronic hepatitis C virus (HCV) infection remains a health burden in people living with human immunodeficiency virus (HIV). Compared to the midpoint prevalence rate of HCV coinfection to be 2.4% in th...
Eligibility Criteria
Inclusion
- Age old than 20 years old
- Patients with human immunodeficiency virus coinfection (HIV) during IFN-based or IFN-free antiviral therapy for hepatitis C virus (HCV) infection
- Patients achieving SVR, defined as undetectable serum HCV RNA at week 12 off-therapy
Exclusion
- Poor access to sites for venipuncture
Key Trial Info
Start Date :
February 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04768517
Start Date
February 9 2021
End Date
March 1 2024
Last Update
February 26 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital, Yun-Lin Branch
Douliu, Taiwan, 640
2
China Medical University Hospital
Taichung, Taiwan, 40447
3
Taichung Veterans General Hospital
Taichung, Taiwan, 40705
4
National Taiwan University Hospital
Taipei, Taiwan, 10002